Drugs / Anastrozole
Anastrozole
also known as
Arimidex · Anastrazole · Anastrozol · Arimidex (anastrozole) · Anastrozole (Arimidex) · 120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, · ANA · Anastrazol · +11 more
Other / unclassified targets CYP19A1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | ARIMIDEX | — | 2000-09-01 – 2011-04-18 | fda.gov ↗ |
| Approved | US (FDA) | ARIMIDEX | — | 1995-12-27 | fda.gov ↗ |
Trials 211 · started per year
today
US approved 1995
3
1
1
1
2
4
2
6
11
13
7
11
10
2
8
5
6
6
10
9
12
12
6
10
9
5
10
5
9
8
5
1
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT07604272 | Jul 2026 → Jun 2028 expected | hernia, double inguinal | Northwestern University | Recruiting | No outcome recorded |
| Phase 1 | NCT07163481 | Oct 2025 → Dec 2026 expected | female breast carcinoma | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04316169 | Oct 2021 → Jan 2027 | female breast carcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT04556773 | Dec 2020 → Aug 2023 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04757532 | Dec 2020 → Mar 2021 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03554044 | Feb 2020 → Dec 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03616587 | Oct 2018 → Sep 2024 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03314298 | Aug 2017 → Apr 2018 | breast disorder | Havah Therapeutics Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03264651 | Feb 2017 → Mar 2018 | breast disorder | Havah Therapeutics Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02779751 | Nov 2016 → Feb 2020 overdue | breast cancer, non-small cell lung carcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02545452 | Sep 2015 → Mar 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02093351 | Sep 2014 → Apr 2015 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02026973 | Mar 2014 → Nov 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01862835 | May 2013 → Sep 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01344031 | Apr → Jul 2011 | estrogen-receptor positive breast cancer, invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01197170 | Sep 2010 → Jan 2021 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03118479 | May → Sep 2010 | Kallmann syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT01155960 | May → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01155947 | May → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT00309855 | Dec 2005 → Aug 2008 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01182181 | Aug → Sep 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00588003 | Mar 2004 → Nov 2009 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02730923 | Apr 2016 → Nov 2019 | endometrial carcinoma, hormone receptor-positive breast cancer, metastatic carcinoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 1/2 | NCT01484041 | Apr 2012 → Dec 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01215292 | Jan 2011 → Mar 2012 | — | University of Washington | Completed | No outcome recorded |
| Phase 2109 trials | ||||||
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07483307 | Mar 2026 → Mar 2030 expected | Her2-receptor negative breast cancer, breast lobular carcinoma, estrogen-receptor positive breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06970912 | Aug 2025 → Dec 2029 expected | female breast carcinoma, hormone receptor-positive breast cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06953882 | Jul 2025 → Sep 2030 expected | Her2-receptor negative breast cancer | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06361940 | Sep 2024 → Dec 2028 expected | breast cancer | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT06086704 | Sep 2024 → Jan 2027 expected | breast cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT05837455 | May 2024 → Nov 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06957379 | Feb 2024 → Jun 2025 overdue | hormone receptor-positive breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06075953 | Feb 2024 → Nov 2028 expected | ductal breast carcinoma in situ | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT06375707 | Jan 2024 → Nov 2025 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05501704 | Oct 2023 → Apr 2027 expected | hormone receptor-positive breast cancer, male breast carcinoma | Jose Pablo Leone | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05826964 | Jun 2023 → Jul 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05190094 | Dec 2022 → Dec 2025 overdue | hormone receptor-positive breast cancer | International Cancer Research Group, United Arab Emirates | Recruiting | No outcome recorded |
| Phase 2 | NCT05297617 | Oct 2022 → Nov 2030 expected | breast cancer | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT05411380 | Oct 2022 → Apr 2024 | breast cancer | wang shusen | Unknown | No outcome recorded |
| Phase 2 | NCT05640778 | Oct 2022 → Oct 2024 | luminal B breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT05467891 | Sep 2022 → Aug 2028 expected | hormone receptor-positive breast cancer | Oana Danciu | Recruiting | No outcome recorded |
| Phase 2 | NCT05524584 | Aug 2022 → Dec 2028 expected | hormone receptor-positive breast cancer | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 2 | NCT04886531 | Jul 2022 → Jun 2026 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | Ruth O'Regan | Recruiting | No outcome recorded |
| Phase 2 | NCT05150652 | Feb 2022 → Dec 2025 overdue | Her2-receptor negative breast cancer | Irada Ibrahim-zada | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04383275 | Aug 2021 → May 2025 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT04666961 | Feb 2021 → Aug 2024 overdue | ductal breast carcinoma in situ | Institut Cancerologie de l'Ouest | Recruiting | No outcome recorded |
| Phase 2 | NCT04719273 | Jan 2021 → Mar 2025 | endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma +1 | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT04569747 | Jan 2021 → Mar 2026 overdue | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04553770 | Oct 2020 → Dec 2026 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04352777 | Sep 2020 → Jun 2025 | hormone receptor-positive breast cancer | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04294225 | Apr 2020 → Dec 2022 | invasive breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04272801 | Apr 2020 → Jun 2024 overdue | female breast carcinoma | Shayna Showalter, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04227327 | Jan 2020 → Jul 2024 | breast cancer | University of Milano Bicocca | Terminated | No outcome recorded |
| Phase 2 | NCT04088110 | Nov 2019 → Nov 2021 | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04075604 | Oct 2019 → Jul 2021 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04113863 | Jun 2019 → Jan 2025 | breast neoplasm | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 2 | NCT03909152 | May 2019 → Sep 2024 | endometrial endometrioid adenocarcinoma, ovarian granulosa cell tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03839823 | Feb 2019 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03691493 | Feb 2019 → Oct 2022 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, metastatic carcinoma in the bone +1 | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT03624244 | Jan 2019 → Jan 2028 expected | uterine corpus endometrial stromal sarcoma | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2 | NCT03944434 | Dec 2018 → Dec 2024 overdue | breast cancer | Fondazione Sandro Pitigliani | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03229499 | Dec 2017 → Jul 2022 | pulmonary arterial hypertension | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT03272477 | Oct 2017 → Jul 2020 | breast cancer | Palleos Healthcare GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03179904 | Aug 2017 → Jul 2024 | HER2 positive breast carcinoma, female breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03211572 | Aug 2017 → Aug 2018 | breast cancer | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03219476 | Feb 2017 → Feb 2020 | invasive breast carcinoma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT02476786 | Jan 2017 → Jan 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT02942355 | Dec 2016 → Jun 2028 expected | female breast carcinoma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02894398 | Sep 2016 → Feb 2023 | hormone receptor-positive breast cancer | iOMEDICO AG | Completed | No outcome recorded |
| Phase 2 | NCT02689921 | Apr 2016 → Dec 2018 | breast neoplasm | Midwestern Regional Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02648477 | Mar 2016 → Apr 2022 | estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer, triple-negative breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02188745 | Mar 2016 → Jan 2024 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03204734 | Jan 2016 → Dec 2020 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02910050 | Jan 2016 → Sep 2018 | breast cancer | Xu fei | Unknown | No outcome recorded |
| Phase 2 | NCT02585388 | Oct 2015 → May 2017 | breast cancer | ARCAGY/ GINECO GROUP | Terminated | No outcome recorded |
| Phase 2 | NCT02441946 | Aug 2015 → Aug 2016 | hormone receptor-positive breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02448420 | Jul 2015 → Sep 2023 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT02440230 | May 2015 → Dec 2021 | breast cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03933618 | Apr 2015 → Mar 2017 | hypogonadism, male | Albany Medical College | Completed | No outcome recorded |
| Phase 2 | NCT02603679 | Feb 2015 → Jul 2021 overdue | estrogen-receptor positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02203331 | Oct 2014 → Oct 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02140437 | Mar 2014 → Dec 2015 | breast carcinoma | Fudan University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01989780 | Jan 2014 → Jun 2018 | breast cancer | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT02000596 | Jan 2014 → Nov 2015 | breast cancer | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT01776008 | Jan 2013 → May 2015 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT02549430 | Oct 2012 → Feb 2017 | breast cancer | Fondazione Sandro Pitigliani | Completed | No outcome recorded |
| Phase 2 | NCT01545336 | Oct 2012 → Jun 2015 | pulmonary arterial hypertension | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01972984 | Oct 2012 → Aug 2014 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01368263 | Sep 2011 → May 2013 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01394211 | Jul 2011 → Apr 2012 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, male breast carcinoma | University of Arizona | Terminated | No outcome recorded |
| Phase 2 | NCT01266213 | Dec 2010 → Jun 2018 | estrogen-receptor positive breast cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01924078 | Oct 2010 → Mar 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01234532 | Oct 2010 → May 2017 | female breast carcinoma, triple-negative breast carcinoma | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT00932152 | Sep 2010 → Jan 2013 | non-small cell lung carcinoma | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 2 | NCT01151215 | Jun 2010 → Jan 2013 | breast cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00921115 | May 2009 → Apr 2015 | invasive breast carcinoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00729859 | Dec 2008 → May 2010 | — | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00687648 | May 2008 → Apr 2010 | female breast carcinoma | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00661531 | Apr 2008 → Jun 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 2 | NCT00481845 | Jan 2008 → Dec 2009 | breast cancer | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00629616 | Oct 2007 → Jun 2015 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT00555477 | Aug 2007 → Dec 2011 | female breast carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00437359 | May 2007 → May 2017 | breast neoplasm | Japan Breast Cancer Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT00467493 | Mar → Sep 2007 | menstrual disorder | Meditrina Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00405938 | Nov 2006 → Jun 2010 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00354640 | Jun 2006 → Oct 2008 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00382057 | May 2006 → Mar 2011 | metabolic syndrome X | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00357110 | Apr 2006 → Oct 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00217659 | Sep 2005 → Jan 2007 | breast cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 2 | NCT00303615 | Jun 2005 → Jun 2007 | breast cancer | Legacy Health System | Terminated | No outcome recorded |
| Phase 2 | NCT00241436 | Jun 2005 → Nov 2006 | gynecomastia disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00213148 | Mar 2005 → Dec 2007 | anovulation | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00094328 | Nov 2004 → May 2008 | precocious puberty | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00136695 | Oct 2004 → Oct 2008 | hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00256217 | Sep 2004 → Dec 2018 | ductal breast carcinoma in situ | Rita Sanghvi, Mehta | Completed | No outcome recorded |
| Phase 2 | NCT00259090 | Apr 2004 → Oct 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00104572 | Mar 2004 → Dec 2013 | depressive disorder, diabetes mellitus, hypogonadism, muscular atrophy +1 | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 2 | NCT00244959 | Jan 2004 → Sep 2007 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00255463 | Jan 2004 → Nov 2005 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00081510 | Dec 2003 → May 2009 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00181688 | Oct 2003 → Mar 2006 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00057941 | Sep 2003 → Jun 2012 | estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00049062 | Sep 2002 → Oct 2007 | breast cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT00055302 | Aug 2002 → Feb 2006 | McCune-Albright syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00235937 | Dec 2001 → Dec 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00128843 | Aug 2001 → Jul 2005 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00179517 | Jun 2001 → Apr 2008 | epilepsy, erectile dysfunction, hypogonadism | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00186121 | Oct 2000 → May 2013 | breast cancer | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00004906 | Oct 1999 → Jun 2001 | breast cancer | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 2 | NCT00287534 | Nov 1996 → Sep 2004 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 340 trials | ||||||
| Phase 3 | NCT07391774 | Feb 2027 → Jul 2029 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT07153757 | Sep 2025 → Sep 2033 expected | female breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06223698 | May 2025 → May 2032 expected | breast cancer | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06492616 | Sep 2024 → Aug 2029 expected | breast cancer | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06507618 | Jul 2024 → Jun 2029 expected | female breast carcinoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT05586802 | Mar 2023 → Apr 2027 expected | Klinefelter syndrome | Georgios Papadakis | Recruiting | No outcome recorded |
| Phase 3 | NCT04158362 | Jun 2020 → Apr 2025 overdue | metastatic malignant neoplasm | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT02532400 | Mar 2016 → Mar 2019 | breast cancer | Ruijin Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02730091 | Feb 2016 → Mar 2020 | breast cancer | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02535221 | Jul 2015 → Jun 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| Phase 3 | NCT02137837 | May 2014 → Dec 2019 | breast cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT02097459 | Mar 2014 → Mar 2024 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01950182 | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02918084 | Jun 2013 → Jun 2028 expected | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00893061 | Mar 2009 → Apr 2012 | breast cancer | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 3 | NCT00944918 | Dec 2008 → Jun 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02338310 | Sep 2008 → Apr 2024 overdue | breast cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01352091 | May 2008 → May 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00902954 | Mar 2008 → Jun 2010 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00543127 | Nov 2007 → Jul 2016 | breast cancer | Spanish Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT00605267 | Oct 2007 → Nov 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00440180 | Mar 2007 → Jun 2014 | obesity disorder, oligospermia | University of Utah | Terminated | No outcome recorded |
| Phase 3 | NCT00541086 | Mar 2007 → Jul 2020 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00301457 | Jun 2006 → Apr 2022 | breast cancer | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00265759 | Jan 2006 → Aug 2012 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00327769 | Nov 2005 → Sep 2007 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00143390 | Apr 2005 → Dec 2010 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00075764 | Apr 2004 → Dec 2012 | breast cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00295620 | Mar 2004 → Jun 2017 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00078832 | Sep 2003 → Dec 2013 | breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 3 | NCT00053898 | Jan 2003 → Mar 2015 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00637182 | Jan 2001 → Jun 2002 | gynecomastia disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00232661 | Aug 2000 → Jan 2003 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00286117 | Mar 1998 → May 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00635713 | May 1997 → Sep 2004 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00291759 | Jan 1996 → Jun 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00300508 | Jan 1996 → ? | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT05362760 | Apr 2022 → Apr 2029 expected | hormone receptor-positive breast cancer | University of Ulm | Recruiting | No outcome recorded |
| Phase 4 | NCT03948568 | Sep 2019 → Jun 2021 | female breast carcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03238703 | Sep 2018 → Mar 2023 | Her2-receptor negative breast cancer, breast carcinoma in situ, female breast carcinoma, invasive breast carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03111615 | May 2018 → May 2019 | female breast carcinoma | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 4 | NCT03490513 | Apr 2018 → May 2025 | hypogonadotropic hypogonadism, obesity disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03421639 | Dec 2017 → Sep 2024 | adenomyosis, dysmenorrhea, infertility disorder | Centre for Endocrinology and Reproductive Medicine, Italy | Unknown | No outcome recorded |
| Phase 4 | NCT02959853 | Jun 2016 → Nov 2018 | hypogonadism, morbid obesity | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02089854 | Nov 2014 → Apr 2019 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01769781 | Jan 2013 → Jul 2015 | endometriosis | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 4 | NCT01553903 | Dec 2011 → May 2013 | breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01127295 | Jun 2010 → Dec 2017 | hormone receptor-positive breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT00537771 | Sep 2007 → Dec 2011 | breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00323479 | Jun 2006 → Jan 2009 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00126360 | Aug 2005 → May 2016 | breast cancer | St George Hospital, Australia | Unknown | No outcome recorded |
| Phase 4 | NCT00544986 | Jun 2005 → Nov 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00286351 | Jan 2005 → ? | endometriosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00082277 | Apr 2004 → Oct 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00286364 | — | infertility disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07212712 | Apr → Dec 2026 expected | vascular disorder | University of British Columbia | Not yet recruiting | No outcome recorded |
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06235931 | Feb 2024 → Dec 2025 overdue | breast neoplasm | Second Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT05167643 | Jan → Oct 2022 | Her2-receptor negative breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01824836 | Jun 2013 → Jun 2022 overdue | estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder, progesterone-receptor positive breast cancer | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| — | NCT01720602 | Nov 2012 → Mar 2015 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT01520467 | Apr 2012 → Jul 2016 | Prader-Willi syndrome, Silver-Russell syndrome | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT00612560 | Nov 2007 → Jan 2011 | breast cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT01004744 | Jul 2007 → Aug 2009 | invasive breast carcinoma | Columbia University | Completed | No outcome recorded |
| — | NCT00983554 | Jun 2005 → May 2009 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| — | NCT01016665 | Apr 2005 → Jul 2007 | breast cancer | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT00437853 | Jun 2003 → Feb 2007 | breast cancer | National Cancer Institute of Mexico | Completed | No outcome recorded |
Also used as a comparator or background therapy in 169 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04088032 Background | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT01763541 Background | Jun 2014 → Feb 2016 | hypertensive disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06218303 Background | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05307705 Background | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT03846583 Background | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02476955 Background | Jun 2015 → May 2019 | endometrial cancer, ovarian cancer | ArQule, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01597193 Background | Apr 2012 → Dec 2015 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00508586 Background | Nov 2007 → Mar 2012 | breast cancer | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00438321 Comparator | Sep 2006 → Feb 2010 | metabolic syndrome X | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT01183390 Comparator | Sep → Oct 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07596212 Background | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07708194 Background | Jun 2025 → Feb 2027 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04539496 Background | May 2018 → Jul 2023 overdue | breast cancer, metastatic neoplasm | Sihuan Pharmaceutical Holdings Group Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01791985 Background | Jul 2012 → Nov 2016 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT01216176 Background | Oct 2008 → Feb 2018 | breast cancer | Joyce Marie Slingerland, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00217399 Background | Jun 2005 → Jul 2009 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 266 trials | ||||||
| Phase 2 | NCT07610720 Background | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07616427 Background | May 2026 → May 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07616453 Background | May 2026 → May 2028 expected | hormone receptor-positive breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07581834 Background | Jan 2026 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07380646 Background | Jan 2026 → Jan 2028 expected | breast cancer, neutropenia, null-cell leukemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07071038 Comparator | Oct 2025 → Aug 2026 overdue | breast cancer | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07101159 Background | Sep 2025 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06486883 Comparator | Jun 2025 → Jan 2027 expected | hormone receptor-positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 2 | NCT06369285 Background | Nov 2024 → Jun 2027 expected | hormone receptor-positive breast cancer | Puma Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06656624 Background | Aug 2024 → Dec 2025 overdue | female breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06179303 Background | Jul 2024 → Mar 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT05896566 Comparator | Jan 2024 → Sep 2025 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT06176534 Comparator | Jan 2024 → Dec 2025 overdue | Her2-receptor negative breast cancer, female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06001762 Background | Oct 2023 → Jan 2025 overdue | breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05949541 Background | Jul 2023 → Jul 2026 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05983107 Background | Jul 2023 → Jul 2026 overdue | hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05549505 Comparator | Feb 2023 → Jul 2024 | breast cancer | Arvinas Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05472792 Comparator | May 2022 → Apr 2027 expected | breast cancer | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04985266 Comparator | Mar 2022 → Sep 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT05041842 Background | Dec 2021 → Apr 2025 overdue | metastatic malignant neoplasm in the brain | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04714619 Background | May → Sep 2021 | female breast carcinoma | MedSIR | Terminated | No outcome recorded |
| Phase 2 | NCT04469764 Background | Oct 2020 → Jul 2027 expected | endometrial carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04436744 Comparator | Sep 2020 → Jul 2021 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04236310 Background | Jan 2020 → Dec 2022 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04059484 Comparator | Oct 2019 → Feb 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT04023292 Comparator | Jul 2019 → Jul 2023 | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03822468 Background | Jun 2019 → Jun 2021 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03910712 Background | Jun 2019 → Jun 2022 | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04256941 Comparator | May 2019 → Sep 2023 | female breast carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03874325 Background | Apr 2019 → Nov 2020 | hormone receptor-positive breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT04012918 Comparator | Aug 2018 → Aug 2020 | breast cancer | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03671330 Background | Aug 2018 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03555877 Background | Mar 2018 → Jul 2022 | breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03321981 Background | Jan 2018 → Oct 2022 | breast carcinoma | Merus B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03184090 Background | Jun 2017 → Oct 2020 | metastatic malignant neoplasm | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03078751 Background | Jun 2017 → Mar 2020 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03024580 Comparator | Mar 2017 → Mar 2020 | breast neoplasm | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02592083 Background | Oct 2015 → Feb 2019 overdue | hormone receptor-positive breast cancer | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02206984 Comparator | Sep 2015 → Jul 2024 | breast cancer | Priscilla McAuliffe | Completed | No outcome recorded |
| Phase 2 | NCT02291913 Background | Dec 2014 → Jan 2019 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02269670 Background | Nov 2014 → Jan 2021 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT02213042 Comparator | Oct 2014 → Jun 2020 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02040857 Background | Jan 2014 → May 2018 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT02072512 Comparator | Jan 2014 → Nov 2015 | breast cancer | Hospital Affiliated to Military Medical Science, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT01814865 Comparator | May → Dec 2013 | estrogen-receptor positive breast cancer | British Columbia Cancer Agency | Withdrawn | No outcome recorded |
| Phase 2 | NCT01723774 Background | Apr 2013 → Apr 2021 overdue | breast neoplasm | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01491737 Background | Feb 2012 → Mar 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01446159 Background | Jun 2011 → Jun 2019 | Her2-receptor negative breast cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT01262274 Comparator | Dec 2010 → Jun 2013 | breast neoplasm | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Terminated | No outcome recorded |
| Phase 2 | NCT00935558 Comparator | Jul 2009 → May 2012 | breast cancer | Inge Marie Svane | Withdrawn | No outcome recorded |
| Phase 2 | NCT00828854 Background | Oct 2008 → Nov 2009 | estrogen-receptor positive breast cancer | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00728949 Comparator | Aug 2008 → Mar 2012 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00738777 Comparator | Jul 2008 → Jun 2022 | breast cancer | The Netherlands Cancer Institute | Suspended | No outcome recorded |
| Phase 2 | NCT00871858 Comparator | Mar 2008 → Nov 2013 | breast cancer | Institut Bergonié | Completed | No outcome recorded |
| Phase 2 | NCT00573755 Background | Dec 2007 → Apr 2013 | breast cancer | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT00570323 Comparator | Dec 2007 → Oct 2016 | breast cancer | Mothaffar Rimawi | Completed | No outcome recorded |
| Phase 2 | NCT00398489 Background | Oct 2006 → ? | breast cancer | Technical University of Munich | Unknown | No outcome recorded |
| Phase 2 | NCT00274469 Comparator | Feb 2006 → Jan 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00240071 Background | Oct 2005 → Mar 2009 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00077168 Background | Apr 2004 → Sep 2017 | breast carcinoma | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| Phase 2 | NCT00077025 Comparator | Jan 2004 → May 2013 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00066378 Background | May 2003 → Aug 2007 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00206414 Background | Jan 2003 → Sep 2006 | breast cancer | Baylor Breast Care Center | Terminated | No outcome recorded |
| Phase 2 | NCT00005908 Background | Jun 2000 → Jan 2008 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00004900 Background | Oct 1999 → Aug 2004 | female breast carcinoma | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00684216 Comparator | Apr 2008 → May 2012 | breast cancer | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 2/3 | NCT00133354 Comparator | Nov 2001 → Aug 2006 | hypopituitarism | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 369 trials | ||||||
| Phase 3 | NCT07349069 Comparator | Mar 2026 → Dec 2030 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07400523 Background | Feb 2026 → Feb 2030 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06585969 Comparator | Jan 2026 | basal-like breast carcinoma, estrogen-receptor positive breast cancer, luminal B breast carcinoma | Danish Breast Cancer Cooperative Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT07174336 Background | Dec 2025 → May 2029 expected | breast cancer, metastatic neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07024173 Comparator | Jul 2025 → Dec 2026 expected | female breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07061717 Comparator | Jul 2025 → Jul 2029 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07019363 Comparator | Jun 2025 → May 2029 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06671912 Comparator | Feb 2025 → Nov 2030 | Her2-receptor negative breast cancer, ductal breast carcinoma in situ, estrogen-receptor positive breast cancer, lobular breast carcinoma in situ | Alliance for Clinical Trials in Oncology | Suspended | No outcome recorded |
| Phase 3 | NCT07190443 Comparator | Feb 2025 → Feb 2034 expected | breast cancer | Japanese Foundation for Cancer Research | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 Comparator | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06044623 Background | Apr 2024 → Oct 2028 expected | breast cancer | Region Örebro County | Recruiting | No outcome recorded |
| Phase 3 | NCT06072781 Comparator | Mar 2024 → Oct 2028 expected | ovarian serous tumor | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05827081 Background | Feb 2024 → Sep 2029 expected | female breast carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05512364 Comparator | Dec 2023 → Nov 2032 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT06016738 Comparator | Nov 2023 → Jun 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05952557 Comparator | Oct 2023 → Mar 2030 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05894239 Background | Sep 2023 → Dec 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 Background | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 Background | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05774951 Comparator | Mar 2023 → Apr 2027 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05780567 Background | Mar 2023 → Dec 2026 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05645536 Background | Dec 2022 → Jun 2028 expected | breast cancer | Tolmar Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05514054 Comparator | Oct 2022 → Oct 2027 expected | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05257395 Background | Mar 2022 → Dec 2025 overdue | female breast carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05439499 Comparator | Mar 2022 → Sep 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04961996 Comparator | Aug 2021 → Aug 2025 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04906395 Background | Jul 2021 → Apr 2026 overdue | female breast carcinoma | Tolmar Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04964934 Comparator | Jun 2021 → Jun 2025 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04852887 Comparator | Jun 2021 → Apr 2031 expected | female breast carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT04134598 Comparator | Feb 2021 → Mar 2030 expected | breast cancer | Careggi University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04711252 Comparator | Jan 2021 → Aug 2026 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04584853 Background | Dec 2020 → Oct 2030 expected | female breast carcinoma | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03820830 Background | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03966898 Background | Jul 2019 → Dec 2022 | female breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03778931 Comparator | May 2019 → Aug 2021 | breast cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03081234 Background | Mar 2018 → Nov 2025 | breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT03425838 Comparator | Nov 2017 → Mar 2023 overdue | breast cancer | Dutch Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02767661 Background | Jul 2017 → Aug 2023 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02763566 Background | Dec 2016 → Mar 2019 overdue | breast cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02278120 Background | Nov 2014 → Aug 2017 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02246621 Background | Nov 2014 → Jan 2017 overdue | breast cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02511639 Background | Jul 2014 → Feb 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 3 | NCT01953588 Comparator | Feb 2014 → Apr 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive ductal breast carcinoma +1 | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01674140 Background | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01602380 Comparator | Oct 2012 → Apr 2016 | hormone receptor-positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01619111 Comparator | Feb 2012 → Jan 2022 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT02995772 Comparator | Nov 2011 → Nov 2018 | breast cancer | Dharmais National Cancer Center Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01402193 Comparator | Jul 2011 → Dec 2014 | female breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT01160211 Background | May 2011 → Mar 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01272037 Background | Feb 2011 → Feb 2023 overdue | ductal breast carcinoma in situ, invasive breast carcinoma, synchronous bilateral breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01248416 Comparator | Nov 2010 → Sep 2016 | isolated short stature | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00887380 Comparator | Sep 2009 → Dec 2024 | breast cancer | Trans Tasman Radiation Oncology Group | Unknown | No outcome recorded |
| Phase 3 | NCT00688194 Comparator | May 2008 → May 2013 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT00556374 Background | Dec 2006 → Oct 2014 | breast cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00310180 Background | Apr 2006 → Mar 2018 overdue | breast adenocarcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00248170 Comparator | Dec 2005 → Sep 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00253422 Comparator | Mar 2004 → Nov 2022 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00256698 Background | Jan 2004 → Apr 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00072462 Comparator | Sep 2003 → Dec 2015 | breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 3 | NCT00066573 Comparator | Jun 2003 → Nov 2010 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00053911 Background | Nov 2002 → Apr 2004 | breast cancer | UNICANCER | Terminated | No outcome recorded |
| Phase 3 | NCT00022672 Background | Jan 2001 → Oct 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00295646 Comparator | Jun 1999 → Mar 2008 | breast cancer | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00784862 Comparator | Jun 1998 → Mar 1999 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00784940 Comparator | Jun 1998 → Mar 2005 | bone disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00784680 Comparator | Apr 1998 → Apr 2004 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00814125 Comparator | Jun 1997 → Dec 2005 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06253702 Background | Jul 2024 → May 2025 | cerebrovascular disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT05161195 Background | Jul 2022 → Jun 2030 expected | metastatic malignant neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04707196 Background | Feb 2021 → Jan 2023 | breast cancer, metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03220178 Background | Jul 2017 → Dec 2021 | breast cancer | Palleos Healthcare GmbH | Terminated | No outcome recorded |
| Phase 4 | NCT01612871 Background | Jun 2012 → Jan 2016 | female breast carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT02137538 Comparator | Nov 2009 → Jun 2018 | isolated short stature | Stanford University | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT05890287 Background | May 2023 → May 2026 overdue | hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT02758431 Comparator | Jul 2016 → Jan 2023 | hypogonadism | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02095184 Comparator | May 2015 → Jul 2024 | breast cancer | University of Maryland, Baltimore | Terminated | No outcome recorded |
| — | NCT02269072 Comparator | Feb 2015 → Feb 2016 | hypertensive disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| — | NCT01897441 Background | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| — | NCT01153672 Background | Nov 2010 → Jul 2012 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT00433173 Comparator | May 2006 → Feb 2011 | metabolic syndrome X | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Suspended | No outcome recorded |
| — | NCT00694733 Comparator | May 2005 → Mar 2024 | obesity disorder | Oregon Health and Science University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic ARIMIDEX® tevapharm.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 387 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anastrozole | “POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO...” PMID 33152284 ↗ Nov 2020355“Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗ “aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “The premenopausal cohort assessed the efficacy and safety of treatment with a non-steroidal aromatase inhibitor (NSAI; letrozole or anastrozole) combined with goserelin and...” NCT03671330 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and...” NCT02203331 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “Patients were randomly assigned (1:1) to receive goserelin 3·6 mg/month plus either anastrozole 1 mg per day and tamoxifen placebo or tamoxifen 20 mg per day and anastrozole...” PMID 22265697 ↗ Jan 2012 “Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total...” NCT03081234 ↗ “Twenty-three obese men (BMI≥35 kg/m2), 35-65 years old, were randomized to weight loss (diet and exercise) plus either anastrozole (AI+WL, n = 12) at 1 mg daily or placebo...” PMID 32499757 ↗ May 2020 “Postmenopausal patients: Letrozole (2.5 mg, orally, once daily, for 5 years) or Anastrozole (1 mg, orally, once daily, for 5 years) or Exemestane (25 mg, orally, once daily,...” NCT07153757 ↗ “We tested this hypothesis in a phase II neoadjuvant trial of anastrozole and fulvestrant combined with gefitinib in postmenopausal women with newly diagnosed ER-positive breast cancer.” PMID 21792626 ↗ Jul 2011 “Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab” NCT04088032 ↗ “Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months.” NCT03078751 ↗ “The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane.” NCT04961996 ↗ “Patients with hormone receptor-positive breast cancer received anastrozole (n = 228) or tamoxifen (n = 223) with or without chemotherapy for 12 weeks before primary surgery.” PMID 16598749 ↗ May 2006 “Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)” NCT06585969 ↗ “Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.” PMID 27908454 ↗ Nov 2016 “Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily” NCT04714619 ↗ “Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively.” NCT07071038 ↗ “Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily” NCT01484041 ↗ “Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day)” NCT05594095 ↗ “Patients were randomized to androgen priming (n = 53): anastrozole 1 mg cycle day (c.d.) 2, 3 and 4, hCG 1250 IU and cetrorelix 3 mg on c.d. 2” PMID 18487212 ↗ May 2008 “Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)” NCT05041842 ↗ “Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)” NCT05362760 ↗ “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT03910712 ↗ “The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.” NCT04088110 ↗ “oral anastrozole 1 mg per day, exemestane 25 mg per day, or letrozole 2·5 mg per day; ipatasertib and aromatase inhibitor group” PMID 42061370 ↗ May 2026 “The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.” NCT02213042 ↗ “Includes anastrozole 1 mg/day, letrozole 2.5 mg/day, or exemestane 25 mg/day, administered orally once daily for 4 cycles.” NCT07618923 ↗ “Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w” NCT02532400 ↗ “["Letrozole","Anastrozole","Exemestane","Tamoxifen","Leuprolide, or other LHRH agonist (per investigator discretion)"]” NCT04569747 ↗ “Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily” NCT01160211 ↗ “either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily” NCT01897441 ↗ “Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)” NCT07610720 ↗ “Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.” NCT05983107 ↗ “The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.” NCT07483307 ↗ “Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination” NCT00255463 ↗ “physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane” NCT06486883 ↗ “Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician)” NCT03425838 ↗ “Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening” NCT03211572 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT06447623 ↗ “Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant.” NCT05949541 ↗ “Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab” NCT01950182 ↗ “Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen” NCT02448420 ↗ “premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane” NCT04383275 ↗ “Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor” NCT06044623 ↗ “Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd” NCT02040857 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “either NCT or NET with goserelin and tamoxifen, followed by goserelin and anastrozole.” PMID 40331570 ↗ May 2025 “letrozole oral 2·5 mg/day, anastrozole oral 1 mg/day, or exemestane oral 5 mg/day” NCT07400523 ↗ “Anastrozole is formulated as tablets of 1 mg strength for oral administration.” NCT02511639 ↗ “Anastrozole or Exemestane or Letrozole administered orally (physician choice)” NCT04188548 ↗ “Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)” NCT01619111 ↗ “NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral” NCT06375707 ↗ “Participants will receive anastrozole 5 mg orally once daily for 6 months.” NCT07604272 ↗ “combined with an aromatase inhibitor (letrozole/anastrozole/exemestane)” NCT06970912 ↗ “Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily” NCT06218303 ↗ “Anastrozole:1 mg once daily on a continuous scheme (tablets , per os)” NCT03079011 ↗ “Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.” NCT01924078 ↗ “Anastrozole: 1.0 mg, orally, once daily (continuous), every 28 days” NCT05861830 ↗ “Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen” NCT05890287 ↗ “Letrozole or anastrozole administered orally (physician choice)” NCT04707196 ↗ “Any brand of letrozole, anastrozole or exemestane may be used” NCT02603679 ↗ “letrozole 2.5 mg, anastrozole 1 mg, or exemestane 20 mg PO qd” NCT06145308 ↗ “letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally” NCT03944434 ↗ “switch to adjuvant anastrozole plus goserelin (ADD group)” PMID 30643455 ↗ Dec 2018 “Letrozole, anastrozole as prescribed per standard of care” NCT04352777 ↗ “Oral combination therapy of enobosarm and anastrozole” NCT03264651 ↗ “Anastrozole 1 mg/day on a continuous dosing schedule” NCT03778931 ↗ “Endocrine therapy (letrozole/anastrozole/exemestane)” NCT07005557 ↗ “Dalpiciclib combined with letrozole or anastrozole” NCT05640778 ↗ “1 mg of anastrozole tablet by mouth once daily or” NCT06369285 ↗ “Anastrozole 1 mg orally once daily continuously.” NCT05827081 ↗ “Letrozole 2,5 mg daily or Anastrozole 1 mg daily” NCT04227327 ↗ “Arimidex (anastrozole) 1mg once daily by mouth” NCT00055302 ↗ “Arimidex® (anastrozole) 1 mg/day by mouth (PO)” NCT00828854 ↗ “anastrozole 1 mg by mouth daily continuously” NCT06953882 ↗ “daily oral anastrozole (Arimidex®) tablets” NCT00022672 ↗ “* AI: Anastrozole, Letrozole or Exemestane” NCT05826964 ↗ “Anastrozole, given per os, 1 mg daily” NCT05297617 ↗ “anastrozole, letrozole, or exemestane” NCT05894239 ↗ “AI: Anastrozole 1mg, 1 time /d, oral” NCT06656624 ↗ “Anastrozole, 1mg, orally once daily” NCT02767661 ↗ “Anastrozole, 1mg, orally once daily” NCT05411380 ↗ “Anastrozole 1mg once a day orally” NCT02910050 ↗ “oral anastrozole (1 mg every day)” PMID 30106636 ↗ Aug 2018 “Anastrozole 1mg once daily” NCT07527806 ↗ “Letrozole or anastrozole” NCT07616427 ↗ “Letrozole or anastrozole” NCT07616453 ↗ “Anastrozole 1mg per day” NCT06176534 ↗ “anastrozole (Arimidex®)” NCT00508586 ↗ “Arimidex (Anastrozole)” NCT01248416 ↗ “Anastrozole” NCT07596212 ↗ “Anastrozole” NCT03948568 ↗ “Anastrozole” NCT06810492 ↗ “Anastrozole” NCT01814865 ↗ “Anastrozole” NCT02995772 ↗ “Anastrozole” NCT00694733 ↗ |
| Known as | 120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, | “120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha',...” NCT04719273 ↗ |
| Known as | ANA | “anastrozole (ANA) in combination with/without metronomic tegafur-uracil (UFT)” NCT01262274 ↗ |
| Known as | Anastrazol | “Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.” NCT03111615 ↗ |
| Known as | Anastrazole | “Aromatase inhibitors such as anastrazole are establishing themselves as a class of drug superior to tamoxifen for the control of estrogen dependent breast cancers and overall...” NCT00126360 ↗19“Aromatase inhibitors (AI) (Anastrazole) and selective estrogen receptor modifiers (SERMS)(clomiphene) increase testosterone production through stimulation of the hypothalamic...” NCT03933618 ↗ “Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients...” NCT03671330 ↗ “Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent” NCT02959853 ↗ “aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)” NCT00240071 ↗ “An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting” NCT00556374 ↗ “With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.” NCT00635713 ↗ “ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE” NCT03624244 ↗ “tamoxifen, Letrozole, Anastrazole, Exemestane, etc.” NCT04023292 ↗ “1mg/day of Anastrazole for 3 months” NCT03421639 ↗ “ARIMIDEX (anastrazole)” NCT00232661 ↗ “Anastrazole (Arimidex)” NCT00605267 ↗ “anastrazole” NCT03321981 ↗ |
| Known as | Anastrozol | “Leucogen combined with Ribociclib (Kisqali®) and Endocrine Therapy (e.g., Letrozole, Anastrozol)” NCT07380646 ↗6“Letrozol or Anastrozol or Exemestane” NCT02592083 ↗ “Arimidex, anastrozol, AstraZeneca” NCT00935558 ↗ “Arimidex® (Anastrozol)” NCT00295620 ↗ |
| Known as | Anastrozole (Arimidex) | “Anastrozole (Arimidex)” NCT06218303 ↗1“Anastrozole (Arimidex)” NCT02000596 ↗ |
| Known as | Anastrozole Tablets | “Drug: Anastrozole Tablets” NCT04906395 ↗ |
| Known as | Arimidex | “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗21“The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.” PMID 10873072 ↗ Jun 2000 “Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment” NCT01602380 ↗ “Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination” NCT00255463 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.” NCT00635713 ↗ “Arimidex® (anastrozole) 1 mg/day by mouth (PO)” NCT00828854 ↗ “Anastrozole 10 mg (Arimidex) orally daily” NCT00438321 ↗ “Anastrozole (Arimidex) 1 mg orally QD” NCT00932152 ↗ “Drug: Anastrozole (Arimidex)” NCT07212712 ↗ “Anastrozole (ARIMIDEX™)” NCT00241436 ↗ “anastrozole (Arimidex®)” NCT00508586 ↗ “Arimidex (Anastrozole)” NCT00181688 ↗ “ARIMIDEX (anastrazole)” NCT00232661 ↗ “Arimidex (Anastrozole)” NCT00133354 ↗ “Arimidex” NCT00295620 ↗ |
| Known as | Arimidex (anastrazole) | “Arimidex (anastrazole)” NCT00240071 ↗ |
| Known as | Arimidex (anastrozole) | “Arimidex (anastrozole)” NCT03118479 ↗ |
| Known as | Arimidex, anastrozol, AstraZeneca | “Arimidex, anastrozol, AstraZeneca” NCT00935558 ↗ |
| Known as | ATZ | “intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)” NCT02545452 ↗ |
| Known as | Depo Lupron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00694733 ↗ |
| Known as | ICI D1033 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1399 ↗ |
| Known as | Nastrosa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1399 ↗ |
| Known as | NSC #719344 | “Combination Anastrozole (NSC #719344) Plus ZD1839” NCT00057941 ↗ |
| Known as | NSC-759855 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1399 ↗ |
| Known as | Rvg-106400 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1399 ↗ |
| Known as | ZD1033 | “Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or...” NCT00077025 ↗ |
| Action | Inhibit | “Arimidex® (Anastrozole) an Aromatase Inhibitor” NCT00022672 ↗1“Cytochrome P450 19A1 inhibitor” CHEMBL1399 ↗ |
| Modality | Other / unclassified | “Anastrozole (Arimidex®) and Letrozole (Femara®) are AIs” NCT02095184 ↗ |
| Route | Oral | “patients receive oral anastrazole daily until disease progression” NCT00004900 ↗ |
| Target | CYP19A1 | “Cytochrome P450 19A1 inhibitor” CHEMBL1399 ↗ |